Erratum to "Relationship between plasma apolipoproteinB concentrations, apolipoproteinB/apolipoproteinA-I and HDL subclasses distribution" [Clinica Chimica Acta 388 (2008) 148-155] (DOI:10.1016/j.cca.2007.10.028);Relationship between plasma apolipoproteinB concentrations, apolipoproteinB/apolipoproeinA-I and HDL subclasses distribution

Clinica Chimica Acta

Volumn 388, Issue 1-2, 2008, Pages 148-155

  Tian, Li ^a,b   Wu, Xinwei ^c   Fu, Mingde ^a,b   Qin, Yang ^a   Xu, Yanhua ^d   Jia, Lianqun ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d Chengdu Hoist Biotechnology Co LTD   (China)

Author keywords

ApoB100; ApoB100 apoA I ratio; Coronary heart disease; HDL subclasses distribution

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; IMMUNODETECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 37249065227     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.01.003     Document Type: Erratum

References (40)

1. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., and Steiner E. High apolipoproteinB, low apolipoproteinA-I, and improvement in the prediction of fatal myocardial infarction(AMORIS Study):a prospective study. Lancet 358 (2001) 2026-2033
2. Williams P.T., Krauss R.M., Nichols A.V., Vranizan K.M., and Woods P.D.S. Identifying the predominant peak diameter of high-density and low-density lipoproteins by electrophoresis. J Lipid Res 31 (1990) 1131-1139
3. Patch W., and Gotto A.M. High density lipoprotein cholesterol, plasma triglyceride, and coronary heart disease: pathophysiology and management. Adv Pharmacol 32 (1995) 375-426
4. Eisenberg S. High-density lipoprotein metabolisms. J Lipid Res 25 (1984) 1017-1058
5. Fruchart J.C., and Ailhaud G. Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance. Clin Chem 38 (1992) 793-797
6. Wu X., Fu M., and Liu B. Study on the immunodetection method of HDL subclasses in human plasma. Chin J Arterioscler 7 (1999) 253-255
7. Barrans A., Jaspard B., Barbaras R., Chap H., Perret B., and Collet X. Prebeta HDL: structure and metabolism. Biochim Biophys Acta 1300 (1996) 73-85
8. Fielding C.J., and Fielding P.E. Molecular physiology of reverse cholesterol transport. J Lipid Res 36 (1995) 211-228
9. Silverman D.I., Ginsburg G.S., and Pasternak R.C. High density lipoprotein subfractions. Am J Med 94 (1993) 363-645
10. Xu Y., and Fu M. Alterations of HDL subclasses in hyperlipidemia. Clin Chim Acta 332 (2003) 95-102
11. Gou L., Fu M., Xu Y., Tian Y., Yan B., and Yang L. Alterations of HDL subclasses in endogenous hypertriglyceridemia. Am Heart J 150 (2005) 1039-1045
12. Jia L., Long S., Fu M., et al. Relationship between total cholesterol/high-density lipoprotein cholesterol ratio, triglyceride/high-density lipoprotein cholesterol ratio, and high-density lipoprotein subclasses. Metab Clin Exp 55 (2006) 1141-1148
13. Tian L., Jia L., Fu M., Xu Y., and Tian H. Alterations of high density lipoprotein subclasses in obese subjects. Lipids 41 (2006) 789-796
14. Jia L., Wu X., Fu M., et al. Relationship between apolipoproteins and the alteration of HDL subclasses in hyperlipidemic subjects. Clin Chim Acta 383 (2007) 65-72
15. Tian L., Fu M., Jia L., et al. Relationship between apolipoprotein concentrations and HDL subclasses distribution. Lipids 42 (2007) 419-426
16. Warnick G.R., Nguyen T., and Albers A.A. Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. Clin Chem 31 (1985) 217-222
17. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
18. Labeur C., Shepherd J., and Rosseneu M. Immunological assays of apolipoproteins in plasma: methods and instrumentation. Clin Chem 36 (1990) 591-597
19. Liu B. Immunoassay of human plasma apolipoproteins and clinical applications. In: Wang K.Q. (Ed). Lipoproteins and atherosclerosis (1995), People's Health Press, Beijing 359-368
20. Stein O., and Stein Y. Atheroprotective mechanisms of HDL. Atherosclerosis 144 (1999) 285-301
21. Fan J.L., McCormick P.A., Krauss R.M., et al. Overexpression of human apolipoproteinB-100 in transgenic rabbits results in increased levels of LDL and decreased levels of HDL. Arterioscler Thromb Vasc Biol 15 (1995) 1889-1899
22. Rizzo M., Taylor J.M., Barbagallo C.M., Berneis K., Blanche P.J., and Krauss R.M. Effects on lipoprotein subclasses of combined expression of human hepatic lipase and human apoB in transgenic rabbits. Arterioscler Thromb Vasc Biol 24 (2004) 141-146
23. 1-HDL levels in hypercholesterolemia are maintained by probucol but reduced by a low-cholesterol diet. Atherosclerosis 138 (1998) 129-134
24. Tatò F., Vega G.L., Tall A.R., and Grundy S.M. Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol 15 (1995) 112-120
25. Tornvall P., Olivecrona G., Karpe F., Hamsten A., and Olivecrona T. Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol 15 (1995) 1086-1093
26. Watanabe H., Miyashita Y., Murano T., Hiroh Y., Itoh Y., and Shirai K. Preheparin serum lipoprotein lipase mass concentration: the effects of age, gender, and types of hyperlipidemias. Atherosclerosis 145 (1999) 45-50
27. Asztalos B.F., Collins D., Cupples L.A., et al. Value of high-density lipoprotein subpopulations in predicting recurrent cardiovascular events in the veterans affairs HDL intervention trial. Arterioscler Thromb Vasc Biol 25 (2005) 2185-2191
28. Kunitake S.T., Mendel C.M., and Hennessy L.K. Interconversion between apolipoproteinA-I-containing lipoproteins of pre-beta and alpha electrophoretic mobilities. J Lipid Res 33 (1992) 1807-1816
29. Rubin E.M., Ishida B.Y., Clift S.M., and Kranss R.M. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci 88 (1991) 434-438
30. Kunitake S.T., La Sala K.J., and Kane J.P. ApolipoproteinA-I-containing lipoproteins with pre-beta electrophoretic mobility. J Lipid Res 26 (1985) 549-555
31. Asztalos B.F., Sloop C.H., Wong L., and Roheim P.S. Two-dimensional electrophoresis of plasma lipoproteins:recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta. 1169 (1993) 291-300
32. Castro G.R., and Fielding C.J. Early incorporation of cell derived cholesterol into preβ-migrating high-density lipoprotein. Biochemistry 27 (1988) 25-29
33. Yusuf P., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries(the INTERGEART study):case-control study. Lancet 364 (2004) 937-952
34. Walldius G., Jungner I., Aastveit A.H., Holme I., Furberg C.D., and Sniderman A.D. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 42 (2004) 1355-1363
35. Tank Ó L.B., Bagger Y.Z., Qin G., Alexandersen P., Larsen P.J., and Christiansen C. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation 111 (2005) 1883-1890
36. Ose L. Might measurements of apolipoproteins replace lipid analyses? Vol. 4 (2003), Medical Products Agency, Sweden 43-45
37. Lind L., Vessby B., and SundstrÖm J. The apolipoproteinB/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol 26 (2006) 406-410
38. Wallenfeldt K., Bokemark L., Wikstrand J., Hulthe J., and Fagerberg B. ApolipoproteinB/ApolipoproteinAI in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 35 (2004) 2248-2252
39. Sviridov D., and Nestel P. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis 161 (2002) 245-254
40. Sasahara T., Nestel P., Fidge N., and Svividov D. Cholesterol transport between cells and high density lipoprotein subfractions from obese and lean subjects. J Lipid Res 39 (1998) 544-554